WealthShield Partners LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 7.9% during the 3rd quarter, Holdings Channel reports. The firm owned 16,191 shares of the medical research company’s stock after buying an additional 1,180 shares during the period. WealthShield Partners LLC’s holdings in Edwards Lifesciences were worth $1,338,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Lazard Asset Management LLC boosted its stake in Edwards Lifesciences by 680.2% in the 2nd quarter. Lazard Asset Management LLC now owns 50,916 shares of the medical research company’s stock worth $4,840,000 after buying an additional 44,390 shares during the last quarter. Stock Yards Bank & Trust Co. acquired a new stake in Edwards Lifesciences in the 2nd quarter worth about $373,000. J.W. Cole Advisors Inc. boosted its stake in Edwards Lifesciences by 4.7% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,521 shares of the medical research company’s stock worth $335,000 after buying an additional 157 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Edwards Lifesciences by 19.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 5,381,049 shares of the medical research company’s stock worth $511,685,000 after buying an additional 860,313 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter worth about $761,000. 80.35% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
EW has been the subject of a number of research analyst reports. Mizuho dropped their price objective on Edwards Lifesciences from $100.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, December 7th. Cowen cut their target price on Edwards Lifesciences from $125.00 to $100.00 in a research report on Friday, October 28th. Canaccord Genuity Group cut their target price on Edwards Lifesciences from $106.00 to $91.00 and set a “hold” rating on the stock in a research report on Friday, October 14th. TheStreet lowered Edwards Lifesciences from a “b-” rating to a “c+” rating in a research report on Friday, November 4th. Finally, Citigroup cut their target price on Edwards Lifesciences from $99.00 to $92.00 and set a “buy” rating on the stock in a research report on Monday, December 12th. Eight investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $98.14.
Edwards Lifesciences Stock Down 3.7 %
Shares of Edwards Lifesciences stock opened at $77.11 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $131.10. The company has a market capitalization of $47.67 billion, a PE ratio of 33.24, a P/E/G ratio of 2.78 and a beta of 1.03. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.83 and a quick ratio of 3.00. The business has a 50-day moving average of $75.55 and a 200-day moving average of $85.05.
Edwards Lifesciences (NYSE:EW – Get Rating) last issued its quarterly earnings data on Thursday, October 27th. The medical research company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.01). The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.34 billion. Edwards Lifesciences had a net margin of 27.20% and a return on equity of 24.75%. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.